Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET.
about
Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase.LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergyA putative pH-dependent nuclear localization signal in the juxtamembrane region of c-MetConditional activation of MET in differentiated skeletal muscle induces atrophy.The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.CD44 is required for two consecutive steps in HGF/c-Met signaling.Targeting HGF/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphomac-MET as a potential therapeutic target and biomarker in cancer.Molecular mechanisms of SH2- and PTB-domain-containing proteins in receptor tyrosine kinase signaling.Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.Autoinhibition of the Ron receptor tyrosine kinase by the juxtamembrane domain.Increased engraftment of hepatic progenitors after activation of the hepatocyte growth factor signaling pathway by protein transduction.Amplification of apoptosis through sequential caspase cleavage of the MET tyrosine kinase receptor.A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3'-kinase activation and endothelial cell migrationProapoptotic function of the MET tyrosine kinase receptor through caspase cleavage.The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells.MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.
P2860
Q24307789-4474A11C-8F1D-4EEA-BCD2-6C66B86CE7B7Q24681561-06D0182A-B30A-4FA5-988F-6AA60FA943F5Q30596960-884634EF-9903-40A5-894E-A8FE7A9F8DE3Q34595811-7098E660-BBD1-466F-AB99-B254F7B477A8Q35103009-419991C5-59BD-4E5E-AE43-A4FB54CE7DF6Q35805198-F22F151D-F043-4DD9-8EAC-D79BCC397711Q36406993-BDE1642C-CD33-4348-AD63-ADE02DBD5181Q37962905-770ADBBE-C067-489F-AF12-4A3C7D68A998Q38167994-B9215B68-D454-49E0-BA29-DD22829CEBD6Q38735120-F91463E1-D68F-49AD-BAA4-75C2D6F53E0AQ39628474-F1FCA4B6-583F-49BF-B9B7-99B73B28975DQ39834676-053CBC84-36DA-4997-9DD4-BCD0B674AFB5Q40191055-0FCF8FEC-09D6-4DF6-95E8-812DA6E2AB57Q40392328-734537BB-10CD-4DA2-B16F-B49850967CBCQ40418357-E2D3AA65-9CA5-4C67-AF2E-BB623FCB4ECAQ42226560-C657F9A3-A180-4EC8-98DC-42C94E499425Q44820646-0BC2A753-CC8B-4B86-8CB5-C197ACF3D604
P2860
Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Loss of the exon encoding the ...... cogenic activation of TPR-MET.
@en
type
label
Loss of the exon encoding the ...... cogenic activation of TPR-MET.
@en
prefLabel
Loss of the exon encoding the ...... cogenic activation of TPR-MET.
@en
P2860
P50
P356
P1433
P1476
Loss of the exon encoding the ...... ncogenic activation of TPR-MET
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.ONC.1202791
P407
P577
1999-07-01T00:00:00Z
P5875
P6179
1024238689